Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial, the drug showed some success in reversing tumor progression when it was tested in combination with cisplatin or paclitaxel.

Ovarian cancer occurs in one out of every 69 women and is the fifth leading cause of cancer death in women, according to the Ovarian Cancer National Alliance. It can be treated if diagnosed early, but most ovarian cancers are caught at later stages. When diagnosed in an advanced stage, women have a 30 percent chance of surviving five years.

More information

To learn more about ovarian cancer, visit the Ovarian Cancer National Alliance.



-- Madeline Vann



SOURCE: OVATURE, press release, Aug. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... services, announced today that Claritas Capital, a Nashville-based private equity firm, has invested ... our expansion plans for some time, and Claritas Capital offers the smart money, ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to ... on Wednesday, June 21. , “Introducing our product on QVC is something we all worked ... our travel pillow to more than 90 million homes in the United States,” said FaceCradle ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology: